[A clinical evaluation of the effect of cephacetrile on bacterial pneumonia. A comparative test with cefazolin by a double blind method (author's transl)]. 1976

K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito

The therapeutic efficacy of cephacetrile (CEC) in bacterial pneumonia was evaluated in contrast with that of cefazolin (CEZ) by a double blind method. Both drugs were administered via intravenous route at a dose of 1 g twice daily for 14 days. 1) Of 81 patients, each 2 from both groups were eliminated from the study because of unknown results. In CEC group, 36 out of 38 obtained a slightly effective or better results (94.7% of effectiveness). In CEZ group, 31 out of 39 showed a similar result and there was no significant difference between the two groups. 2) In more detail, CEC achieved significantly better results in AaDo2 and cardiac insufficiency than CEZ, and this trend was also seen in dyspnea. 3) Regarding background factors, pretreatment severity was slightly in favor of CEC. However, so long as supplementary analysis is concerned, we could not find any relation between the pretreatment severity of symptom and drug efficacy or improvement of symptom. 4) Since there was a slight bias in the background factors, it is difficult to conclude that CEC is better than CEZ in terms of effectiveness. However, we consider CEC is superior to CEZ if compared in details. 5) Both drugs had the same incidence of side effect (6.25%, 3/48 in both groups). When clinical efficacy of CEC in bacterial pneumonia is evaluated together with the incidence of side effect, we may consider that CEC is an effective antibiotic agent equal to or better than CEZ.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011023 Pneumonia, Staphylococcal Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS. Staphylococcal Pneumonia,Staphylococcus Aureus Pneumonia,Pneumonia, Staphylococcus Aureus,Pneumonias, Staphylococcal,Pneumonias, Staphylococcus Aureus,Staphylococcal Pneumonias,Staphylococcus Aureus Pneumonias
D002437 Cefazolin A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. Cephazolin,Ancef,Cefamedin,Cefamezine,Cefazolin Sodium,Cephamezine,Cephazolin Sodium,Gramaxin,Kefzol,Sodium Cephazolin,Totacef,Cephazolin, Sodium,Sodium, Cefazolin,Sodium, Cephazolin
D002505 Cephacetrile A derivative of 7-aminocephalosporanic acid. Cefacetrile,C-36278-Ba,Celospor,Cephacetrile Sodium,C 36278 Ba,C36278Ba,Sodium, Cephacetrile
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
December 1976, The Japanese journal of antibiotics,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
December 1980, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
January 1976, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
September 1986, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
November 1988, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
June 1985, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
October 1980, The Japanese journal of antibiotics,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
August 1979, Ryumachi. [Rheumatism],
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
October 1984, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
K Matsumoto, and Y Noguchi, and Y Uzuka, and Y Kato, and A Saito
March 1978, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Copied contents to your clipboard!